Get started
Author

Rong Chu

Identification of the Major Phosphorylation Site in Bcl-xL Induced by Microtubule Inhibitors and Analysis of Its Functional Significance
2008 · Meenakshi Upreti, Elena N. Galitovskaya, et al. · Journal of Biological Chemistry · 96
Critical role of anti-apoptotic Bcl-2 protein phosphorylation in mitotic death
2013 · J M Eichhorn, N Sakurikar, et al. · Cell Death and Disease · 61
PDF
Cdk1/cyclin B plays a key role in mitotic arrest-induced apoptosis by phosphorylation of Mcl-1, promoting its degradation and freeing Bak from sequestration
2011 · Rong Chu, David T. Terrano, et al. · Biochemical Pharmacology · 61
Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)
2020 · Caron Jacobson, Frederick L. Locke, et al. · Blood · 53
Enkephalin-Encoding Herpes Simplex Virus-1 Decreases Inflammation and Hotplate Sensitivity in a Chronic Pancreatitis Model
2008 · Hong Yang, Terry A McNearney, et al. · Molecular Pain · 46
Key role for Bak activation and Bak-Bax interaction in the apoptotic response to vinblastine
2008 · Meenakshi Upreti, Rong Chu, et al. · Molecular Cancer Therapeutics · 41
PDF
Interim analysis of a phase I dose escalation trial of the antibody drug conjugate (ADC) AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC)
2016 · D. Petrylak, E. Heath, et al. · Annals of Oncology · 31
A phase I study of enfortumab vedotin (ASG-22CE; ASG-22ME): Updated analysis of patients with metastatic urothelial cancer.
2017 · Daniel Peter Petrylak, Raymond P. Perez, et al. · Journal of Clinical Oncology · 28
Regulation of Bax by c-Jun NH2-terminal kinase and Bcl-xL in vinblastine-induced apoptosis
2009 · Rong Chu, Meenakshi Upreti, et al. · Biochemical Pharmacology · 25
A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer
2019 · Deaglan McHugh, Mario Eisenberger, et al. · Investigational New Drugs · 23
A Phase 1 Study of the Anti‐cd37 Antibody‐drug Conjugate Ags67e in Advanced Lymphoid Malignancies. Interim Results
2017 · A. Sawas, K.J. Savage, et al. · Hematological Oncology · 19
PDF
Metabolic Transformation of Antitumor Acridinone C-1305 but Not C-1311 via Selective Cellular Expression of UGT1A10 Increases Cytotoxic Response: Implications for Clinical Use
2012 · Monika Pawlowska, Rong Chu, et al. · Drug Metabolism and Disposition · 17
PDF
Interim analysis of a phase I dose escalation trial of ASG-22CE (ASG-22ME; enfortumab vedotin), an antibody drug conjugate (ADC), in patients (Pts) with metastatic urothelial cancer (mUC)
2016 · J.E. Rosenberg, E. Heath, et al. · Annals of Oncology · 14
Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.
2020 · Frederick Lundry Locke, Nancy L. Bartlett, et al. · Journal of Clinical Oncology · 13
Effects of nitric oxide on expressions of nitrosocysteine and calcium-activated potassium channels in the supraoptic nuclei and neural lobe of dehydrated rats
2006 · Massako Kadekaro, Guangxiao Su, et al. · Neuroscience Letters · 13
Nitric oxide up-regulates the expression of calcium-dependent potassium channels in the supraoptic nuclei and neural lobe of rats following dehydration
2006 · Massako Kadekaro, Guangxiao Su, et al. · Neuroscience Letters · 11
Anti-tumor activity, safety and pharmacokinetics (PK) of AGS15E (ASG-15ME) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC).
2016 · Daniel Peter Petrylak, Elisabeth I. Heath, et al. · Journal of Clinical Oncology · 10
Mitotic arrest-induced phosphorylation of Mcl-1 revisited using two-dimensional gel electrophoresis and phosphoproteomics: nine phosphorylation sites identified
2016 · Rong Chu, Sarah E. Alford, et al. · Oncotarget · 8
PDF
Anti-tumor activity, safety and pharmacokinetics (PK) of ASG-22CE (ASG-22ME; enfortumab vedotin) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC).
2016 · Jonathan E. Rosenberg, Elisabeth I. Heath, et al. · Journal of Clinical Oncology · 7
Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDACTM Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
2024 · Binod Dhakal, Andrew J. Yee, et al. · Blood · 6
Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDACTM Degrader, in Patients with Non-Hodgkin's Lymphoma
2024 · Steven Horwitz, Salvia Jain, et al. · Blood · 5
ABCL-122: Retreatment (reTx) of Patients with Refractory Large B Cell Lymphoma with Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
2020 · Frederick L. Locke, Nancy L. Bartlett, et al. · Clinical Lymphoma Myeloma & Leukemia · 3
Updated Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC® Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
2025 · Binod Dhakal, Andrew Yee, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Long-Term Survival and Gradual Recovery of B Cells in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel)
2021 · Caron A. Jacobson, Frederick L. Locke, et al. · Transplantation and Cellular Therapy · 1
KITE-439: A phase I study of HPV16 E7 T cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers.
2020 · Kedar Kirtane, Erminia Massarelli, et al. · Journal of Clinical Oncology · 1
Works count: 30
Citation count: 596
H-index: 13
I10-index: 17
Year
Topic
Type